MIDDLE EAST AND ASIA PACIFIC ANTIBODY DRUGS MARKET ANALYSIS

Middle East and Asia Pacific Antibody Drugs Market, by Type (Monoclonal Antibodies, Polyclonal Antibody, Bispecific Antibody, Biosimilars, Single Domain Antibody, CAR-T, and Anti-idiotype Antibody), by Disease Indication (Oncology, Neurology, Autoimmune Disorders, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (Middle East (Kingdom of Saudi Arabia, UAE, Israel, Iran, Jordan, Turkey, Qatar, and Rest of Middle East) and Asia Pacific (South East Asia, The Philippines, Malaysia, Singapore, Thailand, Vietnam, Rest of South East Asia, Taiwan, Hong Kong, Macau, Japan, South Korea, India, Australia, China, and Rest of Asia Pacific)) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Mar 2022
Code : CMI4952
Pages :242
Formats :
Excel and PDF
Industry : Pharmaceutical

Middle East And Asia Pacific Antibody Drugs MarketSize and Trends

The high prevalence of chronic diseases such as cancer multiple sclerosis, asthma, rheumatoid arthritis, psoriasis, and others in the Middle East and Asia Pacific region is expected to be the major factor driving the growth of the Middle East and Asia Pacific antibody drugs market over the forecast period. For instance, according to an article published by the Journal of Orthopaedic Surgery and Research in August 2020, the age-standardized prevalence of Rheumatoid Arthritis (RA) in the Tibet Autonomous Region (China) in 2020 was estimated to be 6.30%, wherein the prevalence of RA in women was 2.46% and in men was 9.59%.

Middle East And Asia Pacific Antibody Drugs Market Report Snapshots